Pharmacoeconomic analysis of organic nitrates in antianginal therapy of stable angina

01 July 2011
Written by Solyanik E.V., Eliseeva E.V., Geltser B.I.

  UDK: 616.12‑009.72‑085:615.1:33 | Pages: 110–113 | Read full textDownload PDF 


At determining cost efficiency of organic nitrates of various release forms, the authors have found the advantages for isosorbide‑5‑mononitrate of ordinary and prolonged forms: ‹cost‑efficiency› coefficient was equal to 17.5 and 13.9, respectively. To ensure patient›s relative well‑being when using nitrates of ordinary release form, it costs 71,721.5 rubles; application of prolonged ni‑trates requires 55,458.1 rubles. The ‹cost‑utility› coefficient at outpatient stage is considerably lower than during treatment of stable angina in in‑patient clinic and is 26,131.8 rubles with prolonged ni‑trates and 39,654.7 rubles with nitrates of ordinary release form (difference in coefficients is 48.3 % in favour of nitrates of prolonged forms). To evaluate the economic advantages of one or another therapy program to the full extent, even if they do not have differences by their impact on prognosis at this category of patients, it is required to carry out complex pharmacoeconomic analysis. Applying of ni‑trates of ordinary release form does not work well not merely in terms of economic advantage, but also from positions of utility of such treatments for the patient.

Links to authors:

E.V. Solyanik, E.V. Eliseeva, B.I. Geltser
Vladivostok State Medical University (2 Ostryakova Av. Vladivostok 690950 Russian Federation)

  1. Aronov D.M., Lupanov V.P. The nitrates usege in coronary heart
    disease, Kardiologija. 2006. No. 1. P. 83–85.
    2. Karpov Ju.A. Treatment of patients with stable stenocardia: the
    issue of the new recommendations GFCF, RMZh. 2008. Vol. 16,
    No. 21. P. 1379–1384.
    3. Koncevaja A.V., Kalinina A.M., Spivak E.Ju. The influence of
    learning in the School of Health for patients with coronary heart
    disease on the cost structure for medical treatment (ABC‑and
    VEN‑analysis), Racionalnaja farmakoterapija v kardiologii. 2008.
    no. 3. P. 59–64.
    4. Jagudina R.I., Kulikov A.Ju., Litvinenko M.M. QALY: history,
    methodology and future methods, Farmakojekonomika. 2010.
    No. 1. P. 11–14.
    5. Abrams J. How to use nitrates // Cardiovasc. Drug Ther. 2002.
    Vol.16, No. 6. P. 511–514.
    6. ASC Risk Model // URL: http://www.outcomes‑umassmed.
    org/grase/ascrisk/asc/risk/content (date 21.04.2011).
    7. Cori T., Stolfo Di.G., Sicuro S. et al. Nitroglycerine protects the
    endothelium from ischemia and reperfusion: human mechanistic
    insight, Br. J. Clin. Pharmacol. 2007. Vol. 64. P. 145–150.
    8. Iyenar S.S., Rosano G.M. Effect of antianginal drugs in stable
    angina on predicted mortality risk after surviving a myocardial
    infraction: a preliminary study (METRO), Am. J. Cardiovasc.
    Drugs. 2009. Vol. 9 (5). P. 293–297.
    9. Jansen R., Cleophas T.J., Zwindermann A.H. et al. Chronic nitrate
    therapy in patients with angina and comorbidity, Am. J. Ther.
    2006. Vol. 13, No. 3. P. 188–191.
    10. Laher M., Vaughan A., Griffith C. et al. Cost‑effective benefit
    and health economic of cardiac rehabilitation in elderly subject,
    Abstracts EuroPrevent congress. Madrid (Spain). 2007. P. 103.
    11. Thomas G.R., Di Fabio M., Cori T. et al. Once daily therapy
    isosorbide‑5‑mononitrates causes endothelial dysfunction in
    humans: evidence of a free‑radical‑mediated mechanism, J. Am.
    Coll. Cardiol. 2007. Vol. 49. P. 1289–1295.
    12. Weinstein M.C., Torrance G., McGuire A. et al. QALY: the basics,
    Value and health. 2009. Vol. 12. P. 5–9.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.